V.T. Toan, B.V. Anh
Published: March 30, 2021
Genet. Mol. Res. 20(1): GMR18744
DOI: https://doi.org/10.4238/gmr18744

Cite this Article:
V.T. Toan, B.V. Anh (2021). Aclasta effectively treats osteoporosis in patients with femoral head fractures. Genet. Mol. Res. 20(1): GMR18744. https://doi.org/10.4238/gmr18744

About the Authors
V.T. Toan, B.V. Anh
Corresponding Author: V.T. Toan
Email: vothanhtoan1990@yahoo.com

ABSTRACT

We assessed the effectiveness of Aclasta for osteoporosis in patients with femoral head fractures at Thong Nhat Hospital in Ho Chi Minh City. A total of 156 patients with femoral head fractures and osteoporosis in the orthopedic department at Thong Nhat in Ho Chi Minh City were assigned to a randomized controlled trial from 01 Jan 2013 to 01 Jan 2014, divided into two groups: 75 patients were treated with Aclasta; 81 patients received a placebo. Most of them were followed for at least one year for new bone fractures and T-score index before and one year after treatment. New fractures were found at a rate of about 8% in the Aclasta group and 13.6% in the placebo group, which was significantly different (P < 0.001). Vertebral fractures were different in Aclasta (1.3%) and Placebo groups (3.7%), and the incidence of femoral head fracture was 2.6 and 3.7%. T-score improved significantly after one year in the Aclasta group; the proportion of patients with a T-score in this group changed due to bone deficiency 33.3 and 8%, while in the placebo group, it was 7.4 and 0%; this difference was significant (p <0.001). Using Aclasta for treatment of osteoporosis after femoral head fracture surgery reduces the incidence of new fractures and gives T-score improvement in patients with femoral head fractures, especially in elderly patients.

Key words: Bone Density, Bone density, Fractures, Osteoporosis, Postmenopausal osteopenia, Zoledronic acid.